# Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

> **NCT01059539** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 403 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Cariprazine

## Key facts

- **NCT ID:** NCT01059539
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-28
- **Primary completion:** 2012-02-29
- **Final completion:** 2012-02-29
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2019-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059539, "Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT01059539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*